Navigation Links
Major variation in bladder cancer subtype trends highlights need for focused research
Date:1/4/2012

Researchers are being urged to differentiate between two types of bladder cancer when they carry out studies, after a detailed trends analysis revealed significant differences between the main subtypes of the disease.

A major study of nearly 128,000 American bladder cancer cases, published in the January edition of the urology journal BJUI, shows that bladder cancer rates showed a 9% overall decrease between 1973 and 2007.

However, when the researchers looked at the two main subtypes, which accounted for 94% of the bladder tumours, they found that papillary transitional cell carcinoma (PTCC) increased by 56% over that period and non-papillary transitional cell carcinoma (NPTCC) fell by 53%.

"These two subtypes of bladder cancer are normally categorised as a single disease called transitional cell carcinoma in research studies, but our findings highlight major trend differences over more than three decades" says lead author Dr Yawei Zhang, from the School of Public Health and School of Medicine at Yale University, USA.

"This is a significant finding that underlines the importance of future research differentiating between these two subtypes."

Bladder cancer is the fifth most common cancer in the USA and is responsible for approximately 70,000 new cases and 15,000 deaths a year. Cigarette smoking and occupational exposure to arylamines organic chemicals is thought to account for more than half of the cases in the USA.

The research team used the National Cancer Institute's Surveillance and Epidemiology and End Results data for 1973-2007 to analyse trends in bladder cancer by subtype, disease stage and grade. This revealed the different trends between papillary tumours, that grow on the outside surface of the bladder, and non-papillary tumours, that grow on the inside of the bladder.

Key findings of the study included:

  • The statistics covered 127,614 first primary bladder cancer cases. The majority of the patients (74%) were male and white (92%). Nearly two-thirds of the tumours (65%) were PTCC and 29% were TCC. The other 6% included squamous cell, adenocarcinoma and small cell carcinoma.
  • The overall age-adjusted incidence rates for bladder cancer fell by about 9% between 1973 and 2007 from 16.7 per 100,000 to 15.2. Similar trends were noted in both genders and racial groups.
  • However, significant differences emerged when the research team looked at the two main subtypes. While the age-adjusted rates for NPTCC fell by about 53%, from 7.9 per 100,000 in 1973 to 3.7 per 100,000 in 2007, PTCC increased by 56% from 6.8 to 10.6 per 100,000 over the same period. Similar trends were noted in both genders and racial groups and in different stages of the disease localised, regional and distant.
  • A dramatic increase in the incidence rates of grade four tumours was found between 1998 and 2007, with decreasing trends for grade one, two and three tumours. This is probably due to changes in the grading system introduced in 1998, but the lack of reduction in more aggressive bladder cancer is of great concern. Similar increases were observed for NPTCC and PTCC, genders, racial groups and different disease stages.

"The striking differences in the trends between PTCC and NPTCC suggest that they may be two disease entitles with different causes" concludes Dr Zhang. "Recent survival analysis has also shown that survival rates are substantially higher for PTCC than NPTCC.

"Despite this, no epidemiological studies have investigated the risk factors of these two subtypes separately. Our study suggests that future research must make clear distinctions between PTCC and NPTCC and not just treat them as subtypes of transitional cell carcinoma."


'/>"/>
Contact: Annette Whibley
annette.wizard@gmail.com
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. MP3 Players May Be Major Source of Hearing Loss
2. Neuralstems NSI-189 trial in major depressive disorder receives FDA approval to advance to Phase Ib
3. Majority of B.C. women take prescription drugs during pregnancy: UBC study
4. Major cause of chronic kidney disease-related inflammation is identified
5. Brain tsunamis are clue to helping victims of major head injuries
6. Northern Ireland company makes major breakthrough in cancer treatment
7. Major project to implement new treatments to boost kala-azar elimination strategies
8. Earthquakes Put Millions of Lives, Major Cities at Risk
9. How major signaling pathways are wired to our genome gives new insight into disease processes
10. Policymakers should prepare for major uncertainties with Medicaid expansion
11. Ghost Writing Persists in Major Medical Journals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
(Date:10/12/2017)... ... , ... In the United States, single-family home owners pay ... York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is $7,000 a ... rates, which contributes to the relatively lower cost of living in places like ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm ... California Berkeley, and other leading institutions in announcing the launch of the ... change the way animals are raised for food. , Founding members of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Nvision ... executive staff with the addition of industry sales leader, Thomas (Tom) Slott, as ... the national distribution and sales network, direct the efforts of the surgical sales ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
Breaking Medicine Technology: